Lundbeck Eyes Asian Markets

Denmark-based pharmaceutical company Lundbeck has expanded its agreement with Israel-based partner Teva. The Danish drugmaker will sell Parkinson's disease drug Azilect (rasagline) in six Asian markets: China, South Korea, Hong Kong, Malaysia, Thailand and the Philippines. The full financial terms of deal have not been revealed, but Lundback will pay a share of net sales in the markets to

To read the full article, please choose one of the following options: